ALONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A

Trial Profile

ALONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Efmoroctocog alfa (Primary) ; Rurioctocog alfa
  • Indications Haemophilia A
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms A-LONG; ALONG
  • Sponsors Biogen Idec
  • Most Recent Events

    • 10 Dec 2017 Results of post hoc analysis from A-LONG and ASPIRE studies published in a Bioverativ media release.
    • 01 Nov 2017 According to a Bioverativ media release, longitudinal analysis from the study will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH) 2017.
    • 31 Oct 2017 An interim post hoc analysis from A-LONG and ASPIRE studies published in a Bioverativ Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top